Healthcare & Health Industry Wire — Week of October 13, 2026: Drugmakers sue over Medicare's price model, an AI that spots missed diagnoses, and four Louisiana hospitals for sale
This week's U.S. healthcare scan covers drugmakers' lawsuit over Medicare's new pricing model, a first-in-class antiviral for resistant herpes infections, a $38 million round for AI that finds missed diagnoses, the 2027 Medicare plan ratings, and four Louisiana hospitals for sale.
Coverage window: October 6 – 13, 2026
This edition covers U.S. healthcare developments published or completed between October 6 and October 13, 2026. The brand-drug industry sued the government over Medicare's new international drug-pricing model. The U.S. Food and Drug Administration (FDA) approved a first-in-class antiviral for resistant herpes infections in people with weakened immune systems, cleared several devices, and flagged a fault in a handheld ultrasound system. A clinical-AI company raised $38 million to find hospital patients whose conditions have gone undiagnosed. The Centers for Medicare & Medicaid Services (CMS) published its 2027 plan ratings a week before open enrollment. Four Louisiana hospitals went up for sale.
1. Health-tech funding and products
Healthleap raises $38 million to flag missed diagnoses in hospitals
Status: Healthleap announced the seed and Series A rounds on October 7.
Healthleap raised $38 million in combined seed and Series A funding. An $8 million seed round was co-led by Sequoia Capital and First Round Capital, and a $30 million Series A was led by Hummingbird Ventures. The company kept its valuation private. 1
The San Francisco company sells software that reads hospital records to surface patients who may have an undiagnosed condition, such as malnutrition or delirium. Healthleap connects to a hospital's electronic health record (EHR) — the digital chart that holds a patient's notes, laboratory results and vital signs — and uses language models to pull clinical clues from clinicians' written notes. 1
Each night the software scores every adult inpatient and writes a risk score into the care team's existing workflow, according to the company. Healthleap says the tool flags patients for a closer look, and the diagnosis stays with the care team. 1
Healthleap says it is now live in more than 50 hospitals, including Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare, up from three hospital partners a year earlier. 2
At the Hospital of the University of Pennsylvania, the company says its malnutrition program produced $23.8 million a year in financial impact — $6.3 million from additional reimbursement and $17.5 million from shorter hospital stays. Those figures come from Healthleap. 1
Outro raises $7 million to support supervised medication tapering
Status: Outro announced the pre-seed and seed rounds on October 8.
Outro raised $7 million across pre-seed and seed rounds from investors including Listen Ventures, Cake Ventures, Jason Calacanis's LAUNCH, Actions Capital and Hannah Grey VC. The company supports "deprescribing" — the supervised, step-by-step reduction of a medication — and starts with antidepressants. 3
Outro pairs specially trained clinicians with tapering protocols and patient monitoring, and says the program is available in 14 states. Its co-founder Mark Horowitz is a psychiatrist who has published research on antidepressant tapering; the company plans to extend the model to more drug classes. 3
The third-quarter funding baseline
U.S. digital-health startups raised $3.7 billion across 114 deals in the third quarter of 2026, bringing the year-to-date total to $11.1 billion across 358 deals, according to Rock Health, a digital-health venture fund. The average deal size rose to $31.0 million from $29.5 million in 2025, a sign that capital is concentrating in fewer, larger checks. 4
Loading stats card…
Also this week in health tech: Verana Health, which holds real-world data from an ophthalmology registry covering more than 90 million de-identified patients, and the federated-AI company Bitfount announced a partnership October 8 to speed patient screening for eye-disease clinical trials by combining imaging with EHR data. 5
2. Pharma and device FDA news
A first-in-class antiviral for resistant herpes infections
Status: The FDA approved Hovilpri on October 9 for adults with weakened immune systems.
The FDA approved Hovilpri (pritelivir) tablets for adults whose immune systems are weakened and who have herpes simplex virus (HSV) lesions on the skin or moist tissue — the lips, nostrils, eyes or genitals — that have not responded to other therapies. 6
HSV-1 and HSV-2 are common viruses that cause painful blisters and stay in the body for life, lying dormant between outbreaks. People with compromised immune systems can have more frequent and more serious outbreaks that resist the standard antivirals acyclovir, valacyclovir and famciclovir. 6
The approval rests on a 101-patient phase 3 trial (PRIOH-1, part C; NCT03073967). By day 28, all lesions had healed in 63% of patients taking Hovilpri, against 34% of those taking the investigator's choice of other antivirals. Headache was the most common side effect, and the FDA granted the drug priority review. 6
Loading stats card…
Two cancer approvals and a biosimilar guidance
Status: The FDA approved both new uses during this window.
- Atezolizumab (Tecentriq), October 8. The FDA approved atezolizumab with chemotherapy after surgery for Stage III mismatch repair deficient colon cancer, in patients aged two and older. In the ATOMIC/ML39057 trial (NCT02912559) of 711 adults and one child, the hazard ratio for disease-free survival was 0.50 against chemotherapy alone. 7
- Tucatinib (Tukysa), October 7. The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance treatment for adults with advanced HER2-positive breast cancer after induction therapy. In HER2CLIMB-05 (NCT05132582), median progression-free survival was 24.9 months against 16.3 months for placebo. 8
The FDA also published a final guidance October 9 on postapproval manufacturing changes to biosimilar and interchangeable biosimilar products. 9
Device clearances and one safety alert
Status: Companies announced several 510(k) clearances during this window; the FDA posted one early alert October 9.
Several device makers announced clearances under 510(k), the FDA's premarket path for a new device shown to be substantially equivalent to one already on the market. 10
- RingConn. Shenzhen Ninenovo Technology said October 10 that its smart ring won clearance to measure blood oxygen non-invasively. The FDA record dates the decision October 2. 10
- Urolution Medical. The Maple Grove, Minnesota, company said October 8 that it cleared its OpenFlo urinary catheter, a redesigned Foley catheter for urinary drainage in adults for up to 30 days. 11
- Endovascular Engineering (E2). The company said October 12 that the FDA cleared its Hēlo thrombectomy system and a companion Hēlo Return blood-return system for pulmonary embolism. 12
- Providence Medical Technology. The company said October 13 that it cleared the CORUS PCSS 3D-T, adding 3D-printed porous titanium to its spinal-fusion platform. 13
On October 9 the FDA issued an early alert for the Philips Lumify handheld ultrasound system. Philips told customers September 24 that a software fault can force users to re-register a transducer and block scanning until they reach Wi-Fi or cellular service. The company reported scanning failures and delays in ambulances, aircraft and field settings, and said that as of September 29 it had recorded eight serious injuries and four deaths tied to the problem. 14
Also on October 9, the FDA published a final order that places over-the-counter infant pulse rate and oxygen saturation monitors into class II with special controls, codified at 21 CFR 870.2705. The order moves the device type down from the automatic class III assignment and makes the standard 510(k) path available for baby monitors that use light sensors to track an infant's pulse rate and blood oxygen. 15
3. Insurance and policy
Drugmakers sue over Medicare's international pricing model
Status: The Pharmaceutical Research and Manufacturers of America (PhRMA) filed the complaint October 7 in the U.S. District Court for the District of Columbia.
PhRMA, the brand-drug industry's main trade group, is suing the Trump administration over the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, the mandatory pilot that ties what Medicare pays for certain clinician-administered drugs to prices in peer countries. The complaint argues the "most-favored nation" pilot exceeds Medicare's statutory authority. 16
GLOBE changes how Medicare calculates inflation rebates for some separately payable Part B drugs — the medicines clinicians infuse in clinics and hospitals. It runs from January 1, 2027 to March 31, 2032, and covers beneficiaries in randomly selected areas representing about 25% of Original Medicare. 17
STAT reported that the pilot is unlikely to move much money, because the administration exempted all but a handful of companies in return for voluntary agreements on larger Medicaid drug discounts. 16
Medicare publishes 2027 plan ratings a week before open enrollment
Status: CMS published the 2027 Medicare Advantage and Part D Star Ratings on October 8; open enrollment runs October 15 to December 7, 2026.
CMS rated Medicare Advantage (MA) and Part D plans for 2027. About 37% of the rated MA plans that include drug coverage — 188 contracts — earned four stars or higher. Weighted by enrollment, about 71% of members in those plans sit in contracts rated four or more stars. 18
The average MA drug-plan rating slipped to 3.99 from 4.01 a year earlier, and the average stand-alone Part D rating rose to 3.22 from 3.01. Fifteen MA plans earned five stars, and four carried the low-performing icon. 18
Star ratings run from one to five and measure a plan's quality on items such as cancer screening, medication adherence and customer service. They shape how members compare plans on Medicare Plan Finder and feed quality bonus payments two years later. 18
Loading stats card…
Rural awards continue, and a state plan sues a hospital system
The Rural Health Transformation Program (RHTP), the $50 billion effort created by the Working Families Tax Cuts Act, sent more awards this window. Each entry carries the state, the amount, the project count and what the money buys.
- Iowa, more than $209 million (October 9): robotic-assisted orthopedic surgery for rural hospitals, Iowa's first Maternal-Fetal Medicine Telehealth Network, cancer screening, emergency-medical-services technology, and a health information exchange linking more than 100 facilities. 19
- Louisiana, $37.7 million (October 9): up to $20 million to link public universities and colleges with rural providers, $12.7 million to help 53 rural providers recruit and retain clinicians, and $5 million for health-care career pathways across 39 campuses. 20
- North Carolina, more than $17 million (October 7): $4 million for three mental health clinics, $3 million for medication units treating opioid use disorder in five counties, $4 million for mobile crisis teams in six counties, and $6.7 million for early intervention and maternal mental health. 21
On October 9 the North Carolina State Health Plan and the state treasurer sued Charlotte-based Atrium Health over an affordability program the system announced October 6. The plan covers about 750,000 teachers, state employees and retirees, and the treasurer projects a $500 million deficit for 2026 and $1 billion for 2027. The suit, filed in Wake County Superior Court, seeks a temporary restraining order and a ruling that the program is void. 22
4. Hospital M&A
Four Louisiana hospitals go up for sale
Status: Allegiance Health Management announced the plan October 5; it named no buyers or timeline.
Bossier City-based Allegiance Health Management plans to divest four Louisiana hospitals: Minden Medical Center, Northern Louisiana Medical Center in Ruston, Acadian Medical Center in Eunice and Mercy Regional Medical Center in Ville Platte. Allegiance operates 13 hospitals across Louisiana, Texas and Mississippi, and said the sales aim to position each facility for long-term sustainability. 23
A California sale slips to 2027, and a Colorado network changes hands
- Quorum Health and Banner Lassen Medical Center. Quorum, based in Brentwood, Tennessee, is in the final stages of state reviews to convert to a nonprofit before an affiliate buys Banner Lassen Medical Center in Susanville, California, from Phoenix-based Banner Health. The ownership change is now expected March 31, 2027, later than the December 2026 date first discussed. California's attorney general still must review the sale. 24
- Intermountain Health exits Trinsic. Salt Lake City-based Intermountain Health plans to hand Trinsic, a Colorado clinically integrated network of more than 900 primary care physicians that it formed with UCHealth in 2023, to UCHealth after December 7, according to a WARN notice it filed October 2. 25
Divestitures drive the year's deal flow
Divestitures made up 68% of announced hospital transactions in the first quarter of 2026, up from 45.6% in 2025, according to Kaufman Hall, a health-care advisory firm. Nonprofit systems carrying operating losses and for-profit operators leaving entire states account for much of the shift, and the joint-venture exits follow the same logic of concentrating money on the markets a system keeps. 26
Chicago-based CommonSpirit Health, which is selling or working to sell eight hospitals this year, reported a $430 million operating loss before special charges in fiscal 2026 on revenue of $42.4 billion, as it works through a plan to improve finances by $6 billion over five years. 27
5. Patient health tip: how to stop an antidepressant safely
Antidepressants rank among the most widely prescribed medicines in the United States, and how a person stops one matters as much as how they start. The startup Outro raised $7 million this week to build a supervised tapering service around exactly that gap.
An antidepressant usually helps most when it is taken for at least six months after symptoms ease, and a prescriber should review the decision to stop. Guidance from the Royal College of Psychiatrists, which reflects the United Kingdom's National Institute for Health and Care Excellence (NICE) recommendations, is to step the dose down gradually — a taper — over weeks or months and then stop. 28
An abrupt stop can bring withdrawal symptoms: dizziness, nausea, flu-like feelings, insomnia and anxiety. A slow taper lowers the chance of those symptoms and of the depression or anxiety returning. 28
A workable plan starts with a conversation with the prescriber before any change, then a step-down schedule agreed in advance. As the dose drops, report symptoms so the pace can be adjusted; for someone who has taken an antidepressant for years, a taper can run for many months. 28
The Department of Health and Human Services signaled policy interest in the same area in May 2026, when it laid out an action plan to curb psychiatric overprescribing and to support tapering for patients who are not benefiting from their medication. 29
Bottom line
Three things to watch. A federal court will decide whether the GLOBE Model can start on January 1, 2027, in the middle of a 2027 enrollment season. Medicare open enrollment opens October 15, and the new star ratings are a fast way to compare plans on quality. The FDA kept clearing devices, with the week's approvals spanning a smart ring, a urinary catheter and a thrombectomy system.
References
- 1
- 2Healthleap raises $38M to help hospitals find patients with undiagnosed conditions
beckershospitalreview.com
- 3Fierce Healthcare Fundraising Tracker '26
fiercehealthcare.com
- 4
- 5
- 6
- 7
- 8
- 9
- 10510(k) Premarket Notification K260490
accessdata.fda.gov
- 11
- 12E2 Secures Dual FDA Clearances for the Hēlo Platform
prnewswire.com
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22North Carolina State Health Plan sues Atrium Health over affordability program
beckershospitalreview.com
- 23Allegiance Health Management to sell 4 Louisiana hospitals
beckershospitalreview.com
- 24Quorum affiliate's acquisition of Banner hospital nears final review
beckershospitalreview.com
- 25Why Ardent, CHS are exiting joint ventures
beckershospitalreview.com
- 26M&A Quarterly Activity Report: Q1 2026
kaufmanhall.com
- 27CommonSpirit to sell 8 hospitals in 2026
beckershospitalreview.com
- 28Stopping antidepressants
rcpsych.ac.uk
- 29
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.